Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Open Access
- 1 October 2008
- journal article
- case report
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 31 (10), 900-4
- https://doi.org/10.1007/BF03346439
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classificationEndocrine-Related Cancer, 2007
- Surveillance for Early Detection of Aggressive Parathyroid Disease: Carcinoma and Atypical Adenoma in Familial Isolated Hyperparathyroidism Associated With a Germline HRPT2 MutationJournal of Bone and Mineral Research, 2006
- Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and HyperplasiasThe American Journal of Surgical Pathology, 2006
- Diagnosis of Parathyroid Tumors in Familial Isolated Hyperparathyroidism with HRPT2 Mutation: Implications for Cancer SurveillanceJournal of Clinical Endocrinology & Metabolism, 2006
- Genetic Analyses of theHRPT2Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid TumorsJournal of Clinical Endocrinology & Metabolism, 2004
- Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid CarcinomaClinical Cancer Research, 2004
- HRPT2 mutations are associated with malignancy in sporadic parathyroid tumoursJournal of Medical Genetics, 2003
- Parathyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2001
- Loss of The Retinoblastoma Tumor-Suppressor Gene in Parathyroid CarcinomaNew England Journal of Medicine, 1994
- Parathyroid carcinoma.A study of 70 casesCancer, 1973